Skip to main content

Table 1 Patient characteristics of the 94 patients with metastatic breast cancer receiving first line docetaxel + cisplatin combination chemotherapy +/- the protone pump inhibitor esomeprazole

From: Intermittent high dose proton pump inhibitor enhances the antitumor effects of chemotherapy in metastatic breast cancer

 

Whole population (n = 94)

Arm A (no ESOM) (n = 32)

Arm B (lower dose ESOM) (n = 31)

Arm C (higher dose ESOM) (n = 31)

Median Age (years)

52 (31-67)

52 (31-66)

50 (36-64)

54 (33-67)

Amenorrhea

    

 Premenopausal

30 (31.9 %)

10 (31.3 %)

11 (35.5 %)

9 (29.0 %)

 Postmenopausal

64 (68.1 %)

22 (68.8 %)

20 (64.5 %)

22 (71.0 %)

Advanced or metastatic

    

 de novo metastatic

8 (8.5 %)

1 (3.1 %)

4 (12.9 %)

3 (9.7 %)

 Metastatic

86 (91.5 %)

31 (96.9 %)

27 (87.1 %)

28 (90.3 %)

  Median DFI (years)

3.3

3.2

3.2

3.4

No. of metastatic sites

    

 1

23 (24.5 %)

10 (31.3 %)

6 (19.4 %)

7 (22.6 %)

 2

37 (39.4 %)

9 (28.1 %)

15 (48.4 %)

13 (41.9 %)

 ≥3

34 (36.2 %)

13 (40.6 %)

10 (32.3 %)

11 (35.5 %)

Metastatic sites

    

 Visceral

69 (73.4 %)

25 (78.1 %)

22 (71.0 %)

22 (71.0 %)

  Lung

50 (53.2 %)

18 (56.3 %)

16 (51.6 %)

16 (51.6 %)

  Liver

39 (41.5 %)

15 (46.9 %)

11 (35.5 %)

13 (41.9 %)

 Nonvisceral

25 (26.6 %)

7 (21.9 %)

9 (29.0 %)

9 (29.0 %)

  Bone

38 (40.4 %)

10 (31.3 %)

15 (48.4 %)

13 (41.9 %)

ER status

    

 Positive

61 (64.9 %)

19 (59.4 %)

22 (71.0 %)

20 (64.5 %)

 Negative

33 (35.1 %)

13 (40.6 %)

9 (29.0 %)

11 (35.5 %)

PR status

    

 Positive

57 (60.6 %)

20 (62.5 %)

18 (58.1 %)

19 (61.3 %)

 Negative

37 (39.4 %)

12 (37.5 %)

13 (41.9 %)

12 (38.7 %)

HER-2 status

    

 Positive

15 (16.0 %)

4 (12.5 %)

5 (16.1 %)

6 (19.4 %)

 Negative

79 (84.0 %)

28 (87.5 %)

26 (83.9 %)

25 (80.6 %)

Prior chemotherapy

    

 Adjuvant/neoadjuvant

    

  Anthracyclines only

34 (36.2 %)

12 (37.5 %)

11 (35.5 %)

11 (35.5 %)

  Taxanes only

2 (2.1 %)

0 (0 %)

1 (3.2 %)

1 (3.2 %)

  Both antracyclines and taxanes

41 (43.6 %)

16 (50.0 %)

12 (38.7 %)

13 (41.9 %)

  others

6 (6.4 %)

0 (0 %)

3 (9.7 %)

2 (6.5 %)

 None

11 (11.7 %)

4 (12.5 %)

4 (12.9 %)

4 (12.9 %)

Prior endocrine therapy

    

 1

44 (46.8 %)

15 (46.9 %)

13 (41.9 %)

16 (51.6 %)

 2

19 (20.2 %)

5 (15.6 %)

9 (29.0 %)

5 (16.1 %)

 ≥3

5 (5.3 %)

2 (6.3 %)

2 (6.5 %)

1 (3.2 %)

 None

26 (27.7 %)

10 (31.3 %)

7 (22.6 %)

9 (29.0 %)

Subgroup

    

 Triple negative

15 (16.0 %)

7 (21.9 %)

2 (6.5 %)

6 (19.4 %)

 Her-2 positive

11 (11.7 %)

3 (9.4 %)

5 (16.1 %)

3 (9.7 %)

 Luminal Type

68 (72.3 %)

22 (68.8)

24 (77.4)

22 (71.0)

  1. ESOM esomeprazole, DFI disease free survival; de novo metastatic: metastatic breast cancer is diagnosed when there is no prior history of breast cancer
  2. Demographic and baseline disease characteristics of the intention-to-treat population were generally well balanced between treatment arms (all p > 0.05)
Back to article page

Journal of Experimental & Clinical Cancer Research

ISSN: 1756-9966

Contact us